» Articles » PMID: 33776988

Donor/Recipient HLA Molecular Mismatch Scores Predict Primary Humoral and Cellular Alloimmunity in Kidney Transplantation

Abstract

Donor/recipient molecular human leukocyte antigen (HLA) mismatch predicts primary B-cell alloimmune activation, yet the impact on donor-specific T-cell alloimmunity (dnDST) remains undetermined. The hypothesis of our study is that donor/recipient HLA mismatches assessed at the molecular level may also influence a higher susceptibility to the development of posttransplant primary T-cell alloimmunity. In this prospective observational study, 169 consecutive kidney transplant recipients without preformed donor-specific antibodies (DSA) and with high resolution donor/recipient HLA typing were evaluated for HLA molecular mismatch scores using different informatic algorithms [amino acid mismatch, eplet MM, and Predicted Indirectly Recognizable HLA Epitopes (PIRCHE-II)]. Primary donor-specific alloimmune activation over the first 2 years posttransplantation was assessed by means of both dnDSA and dnDST using single antigen bead (SAB) and IFN-γ ELISPOT assays, respectively. Also, the predominant alloantigen presenting pathway priming DST alloimmunity and the contribution of main alloreactive T-cell subsets were further characterized . Pretransplantation, 78/169 (46%) were DST+ whereas 91/169 (54%) DST-. At 2 years, 54/169 (32%) patients showed detectable DST responses: 23/54 (42%) dnDST and 31/54 (57%) persistently positive (persistDST+). 24/169 (14%) patients developed dnDSA. A strong correlation was observed between the three distinct molecular mismatch scores and they all accurately predicted dnDSA formation, in particular at the DQ locus. Likewise, HLA molecular incompatibility predicted the advent of dnDST, especially when assessed by PIRCHE-II score (OR 1.014 95% CI 1.001-1.03, p=0.04). While pretransplant DST predicted the development of posttransplant BPAR (OR 5.18, 95% CI=1.64-16.34, p=0.005) and particularly T cell mediated rejection (OR 5.33, 95% CI=1.45-19.66, p=0.012), patients developing dnDST were at significantly higher risk of subsequent dnDSA formation (HR 2.64, 95% CI=1.08-6.45, p=0.03). experiments showed that unlike preformed DST that is predominantly primed by CD8+ direct pathway T cells, posttransplant DST may also be activated by the indirect pathway of alloantigen presentation, and predominantly driven by CD4+ alloreactive T cells in an important proportion of patients. donor-specific cellular alloreactivity seems to precede subsequent humoral alloimmune activation and is influenced by a poor donor/recipient HLA molecular matching.

Citing Articles

donor-specific anti-HLA antibody risk stratification in kidney transplantation using a combination of B cell and T cell molecular mismatch assessment.

Chou-Wu E, Niemann M, Youngs D, Gimferrer I Front Immunol. 2025; 16:1508796.

PMID: 40070832 PMC: 11893832. DOI: 10.3389/fimmu.2025.1508796.


Anti-Human Leukocyte Antigen Antibody Detection from Terasaki's Humoral Theory to Delisting Strategies in 2024.

San Segundo D, Comins-Boo A, Lopez-Hoyos M Int J Mol Sci. 2025; 26(2).

PMID: 39859344 PMC: 11766285. DOI: 10.3390/ijms26020630.


Improving long-term kidney allograft survival by rethinking HLA compatibility: from molecular matching to non-HLA genes.

Mattoo A, Jaffe I, Keating B, Montgomery R, Mangiola M Front Genet. 2024; 15:1442018.

PMID: 39415982 PMC: 11480002. DOI: 10.3389/fgene.2024.1442018.


Allogeneic mesenchymal stromal cell therapy in kidney transplantation: should repeated human leukocyte antigen mismatches be avoided?.

Bezstarosti S, Erpicum P, Maggipinto G, Dreyer G, Reinders M, Meziyerh S Front Genet. 2024; 15:1436194.

PMID: 39399215 PMC: 11466828. DOI: 10.3389/fgene.2024.1436194.


Allogeneic HLA Humoral Immunogenicity and the Prediction of Donor-Specific HLA Antibody Development.

Jucaud V Antibodies (Basel). 2024; 13(3).

PMID: 39189232 PMC: 11348167. DOI: 10.3390/antib13030061.


References
1.
Kramer C, Koster J, Haasnoot G, Roelen D, Claas F, Heidt S . HLA-EMMA: A user-friendly tool to analyse HLA class I and class II compatibility on the amino acid level. HLA. 2020; 96(1):43-51. PMC: 7317360. DOI: 10.1111/tan.13883. View

2.
Coemans M, Susal C, Dohler B, Anglicheau D, Giral M, Bestard O . Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015. Kidney Int. 2018; 94(5):964-973. DOI: 10.1016/j.kint.2018.05.018. View

3.
Tambur A, McDowell H, Hod-Dvorai R, Abundis M, Pinelli D . The quest to decipher HLA immunogenicity: Telling friend from foe. Am J Transplant. 2019; 19(10):2910-2925. DOI: 10.1111/ajt.15489. View

4.
Bestard O, Nickel P, Cruzado J, Schoenemann C, Boenisch O, Sefrin A . Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol. 2008; 19(7):1419-29. PMC: 2440291. DOI: 10.1681/ASN.2007050539. View

5.
Herrera O, Golshayan D, Tibbott R, Salcido Ochoa F, James M, Marelli-Berg F . A novel pathway of alloantigen presentation by dendritic cells. J Immunol. 2004; 173(8):4828-37. DOI: 10.4049/jimmunol.173.8.4828. View